These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review of atazanavir: a novel HIV protease inhibitor. Fuster D; Clotet B Expert Opin Pharmacother; 2005 Aug; 6(9):1565-72. PubMed ID: 16086644 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Le Tiec C; Barrail A; Goujard C; Taburet AM Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994 [No Abstract] [Full Text] [Related]
8. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future? TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613 [No Abstract] [Full Text] [Related]
9. Lack of interaction between atazanavir and lansoprazole. Kosel BW; Storey SS; Collier AC AIDS; 2005 Mar; 19(6):637-8. PubMed ID: 15802988 [No Abstract] [Full Text] [Related]
10. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183 [TBL] [Abstract][Full Text] [Related]
11. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. Khanlou H; Farthing C J Acquir Immune Defic Syndr; 2005 Aug; 39(4):503. PubMed ID: 16010179 [No Abstract] [Full Text] [Related]
12. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients. Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300 [TBL] [Abstract][Full Text] [Related]
13. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Ford J; Boffito M; Maitland D; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A J Antimicrob Chemother; 2006 Nov; 58(5):1009-16. PubMed ID: 16984898 [TBL] [Abstract][Full Text] [Related]
14. PI monotherapy effective as maintenance. AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054 [No Abstract] [Full Text] [Related]
15. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323 [TBL] [Abstract][Full Text] [Related]
16. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. Karlström O; Josephson F; Sönnerborg A J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658 [TBL] [Abstract][Full Text] [Related]
17. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens. Regazzi M; Villani P; Gulminetti R; Cusato M; Brandolini M; Tinelli C; Barassi A; Maserati R; Sighinolfi L; D'Arminio Monforte A; Melzi D'Eril GV Ther Drug Monit; 2011 Jun; 33(3):303-8. PubMed ID: 21544015 [TBL] [Abstract][Full Text] [Related]
19. Atazanavir: in pediatric patients with HIV-1 infection. Deeks ED Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486 [TBL] [Abstract][Full Text] [Related]
20. Drug interactions. Kaletra and atazanavir. TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919 [No Abstract] [Full Text] [Related] [Next] [New Search]